Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 4/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | BCL6 | P41182 | 1/20 | 0.35 |
| ▸ | BCOR | Q6W2J9 | 1/20 | 0.35 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.35 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6811912 | 0.80 | CYP3A4 (0.51) | CYP3A4CYP2C9BCAT2 | |
| SCHEMBL29503125 | 0.77 | AR (0.53) | PARP1BCAT2AR | |
| SCHEMBL27761288 | 0.76 | CYP3A4 (0.40) | HSD11B1CYP3A4CYP2C9MRGPRX4KCNK2 | |
| SCHEMBL6811914 | 0.75 | CYP3A4 (0.47) | HSD11B1CYP3A4CYP2C9BCAT2 | |
| SCHEMBL1086197 | 0.74 | NPFFR2 (0.58) | HSD11B1PARP1CHEK2 | |
| SCHEMBL31144967 | 0.74 | NPFFR2 (0.58) | HSD11B1PARP1CHEK2 | |
| SCHEMBL4294249 | 0.74 | HSD11B1 (0.45) | HSD11B1PARP1BCAT2ARCHEK2 | |
| SCHEMBL30875154 | 0.73 | PDE7A (0.53) | HSD11B1CYP3A4CYP2C9 | |
| SCHEMBL1403756 | 0.73 | PDE7A (0.53) | HSD11B1CYP3A4CYP2C9 | |
| SCHEMBL28229893 | 0.73 | HSD17B10 (0.46) | CYP3A4CYP2C9PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDICK A/S (DK) | 2010-02-18 | — | — | US | claimed |
| EP-1881961-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2008-01-30 | — | — | EP | claimed |
| JP-2007523865-A | — | — | 2007-08-23 | — | — | JP | claimed |
| WO-2006120178-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | WO | claimed |
| US-7129235-B2 | Amides useful for treating pain | ABBOTT LABORATORIES (US) | 2006-10-31 | — | — | US | claimed |
| EP-1646621-A2 | NOVEL AZAHETEROCYCLIC AMIDES USEFUL FOR TREATING PAIN | Abbott Laboratories (US) | 2006-04-19 | — | — | EP | claimed |
| US-20050080095-A1 | administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I | ABBVIE INC. | 2005-04-14 | — | — | US | claimed |
| WO-2005007642-A2 | NOVEL AZAHETEROCYCLIC AMIDES USEFUL FOR TREATING PAIN | ABBOTT LABORATORIES (US) | 2005-01-27 | — | — | WO | claimed |
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDICK A/S (DK) | 2010-02-18 | — | — | US | disclosed |
| US-20080153809-A1 | NOVEL AMIDES USEFUL FOR TREATING PAIN | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
| US-7348343-B2 | Amides useful for treating pain | ABBOTT LABORATORIES INC. (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1881961-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2008-01-30 | — | — | EP | disclosed |
| US-20070010557-A1 | Novel amides useful for treating pain | ABBVIE INC. | 2007-01-11 | — | — | US | disclosed |
| WO-2006120178-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | WO | disclosed |
| US-7129235-B2 | Amides useful for treating pain | ABBOTT LABORATORIES (US) | 2006-10-31 | — | — | US | disclosed |
| US-20050080095-A1 | administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I | ABBVIE INC. | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | RPS12, GPR119, ATP12A | HSD11B1 66/4885CYP3A4 1149/4885CYP2C9 1431/4885 |
| US-20050080095-A1 | administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I | TRPV1, OPRL1, TRPV6 | HSD11B1 4395/4885CYP3A4 1354/4885CYP2C9 1012/4885 |
| US-20070010557-A1 | Novel amides useful for treating pain | OPRL1, PDE6B, PDE6G | HSD11B1 3143/4885CYP3A4 1458/4885CYP2C9 433/4885 |
| US-20080153809-A1 | NOVEL AMIDES USEFUL FOR TREATING PAIN | OPRL1, OPRK1, OPRD1 | HSD11B1 2583/4885CYP3A4 1278/4885CYP2C9 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.